Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).

Antimicrobial agents and chemotherapy - 1 Apr 2016

Flamm Robert K, Mendes Rodrigo E, Hogan Patricia A, Streit Jennifer M, Ross James E, Jones Ronald N

Abstract excerpt

Thelinezolidexperience andaccuratedetermination ofresistance (LEADER) surveillance program has monitored linezolid activity, spectrum, and resistance since 2004. In 2014, a total of 6,865 Gram-positive pathogens from 60 medical centers from 36 states were submitted. The organism groups evaluated wereStaphylococcus aureus(3,106), coagulase-negative staphylococci (CoNS; 797), enterococci (855),Streptococcus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enterococcus
Share to Linezolid
Share to Public Health Surveillance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ribosomal Proteins

Share to RNA, Ribosomal, 23S

Share to Staphylococcal Infections

Share to Streptococcal Infections

Share to Streptococcus pneumoniae

Source

Open in PubMed Open full text

Identifiers

PMID: 26833165
DOI: 10.1128/AAC.02803-15
PMCID: PMC4808230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).PMID 26833165Read ↗

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)Semantic proximity Read ↗

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Semantic proximity Read ↗

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countriesSemantic proximity Read ↗

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Semantic proximity Read ↗

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.Semantic proximity Read ↗

The emerging problem of linezolid-resistant <i>Staphylococcus</i>Semantic proximity Read ↗

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesSemantic proximity Read ↗

Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12)Semantic proximity Read ↗

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates.Semantic proximity Read ↗

Global Expansion of Linezolid-Resistant Coagulase-Negative StaphylococciSemantic proximity Read ↗

Molecular Characteristics and Antimicrobial Resistance of Linezolid-Resistant Staphylococcus aureus in Osteoarticular Infections: A 11-Year Study From a Hospital in Xi’anSemantic proximity Read ↗

Mechanisms of Linezolid Resistance among Coagulase-Negative Staphylococci Determined by Whole-Genome SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.